Serum mesothelin is a biomarker for disease progression and mortality in mesothelioma - Milan 2023

Optimising diagnostic tools and treatment for malignant pleural effusion and mesothelioma

Chair(s): Valentina Pinelli, Kevin Blyth

Session type: Oral presentation

Serum mesothelin is a biomarker for disease progression and mortality in mesothelioma

Geri Lynch

EVENTS HOME

Previous presentation

Next presentation

Session content

Serum mesothelin is a biomarker for disease progression and mortality in mesothelioma

Geri Lynch

Replay

Poster

Abstract

Slides

Defining a new diagnostic biomarker panel for malignant pleural mesothelioma using a novel proteomic technique.

Eline Schillebeeckx

Replay

Poster

Abstract

Slides

Pleural fluid mesothelin as a further diagnostic tool in subjects with a histological diagnosis of non specific pleuritic (NSP)

Federica Novelli

Replay

Poster

Abstract

Slides

Exhaled breath analysis predicts treatment response in malignant pleural mesothelioma patients.

Ellen Heirwegh

Replay

Poster

Abstract

Slides

The Scottish Mesothelioma Network: Impact of a national MDT on overall survival in pleural mesothelioma

Matthew Tate

Replay

Poster

Abstract

Slides

Qualitative study of patient priorities in the malignant pleural effusion pathway

Dinesh Addala

Replay

Poster

Abstract

Slides

To study the efficacy of time dependant vs volume dependant chest drain removal protocol for talc slurry pleurodesis in patients with malignant pleural effusion

Richa Gupta

Replay

Poster

Abstract

Slides

Does a novel Indwelling Pleural Catheter drainage system improve patient experience?

Hugh Welch

Replay

Poster

Abstract

Slides

Pressurized Intra-Thoracic Aerosol Chemotherapy (PITAC): preliminary results in malignant pleural effusion

Maria Giovanna Mastromarino

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}